{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:00:23Z","timestamp":1791414023973,"version":"4.3.3"},"reference-count":48,"publisher":"Royal College of General Practitioners","issue":"708","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Gen Pract"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Osteoarthritis (OA) of the knee is a common cause of chronic pain. Analgesics that are currently available have limited efficacy and may be poorly tolerated. Tricyclic antidepressants are used as analgesics for other chronic conditions, but they have not been evaluated as analgesics in OA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the analgesic efficacy of nortriptyline in people with knee OA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and setting<\/jats:title><jats:p>A two-arm, parallel-group, 1:1, double-blind, randomised, placebo-controlled trial in Christchurch, New Zealand.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Participants were recruited from orthopaedic outpatient clinics, primary care, and through public advertising. Adults with knee OA and a pain score of \u226520 points on the 50-point Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain subscale were randomised to receive either nortriptyline or identical placebo for 14 weeks. The primary outcome was knee pain at 14 weeks measured using the WOMAC pain subscale. Secondary outcomes included: function; stiffness; non-steroidal anti-inflammatory drug, opioid, and\/or paracetamol use; each participant\u2019s global assessment; and adverse effects at 14 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 205 randomised participants, 201 (98.0%) completed follow-up at 14 weeks. The baseline-adjusted mean WOMAC pain subscale score at week 14 was 6.2 points lower (95% confidence interval = \u22120.26 to 12.6, <jats:italic>P<\/jats:italic> = 0.06) in the nortriptyline arm versus the placebo arm. Differences in secondary outcomes generally favoured the nortriptyline arm, but were small and unlikely to be clinically relevant. However, the following were all more commonly reported by participants taking nortriptyline than those taking a placebo: dry mouth (86.9% versus 51.0%, respectively, <jats:italic>P<\/jats:italic>&lt;0.001), constipation (58.6% versus 30.4%, respectively, <jats:italic>P<\/jats:italic>&lt;0.001), and sweating (31.3% versus 20.6%, respectively, <jats:italic>P<\/jats:italic> = 0.033).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study suggests nortriptyline does not significantly reduce pain in people with knee OA. The adverse effect profile was as expected.<\/jats:p><\/jats:sec>","DOI":"10.3399\/bjgp.2020.0797","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T01:50:35Z","timestamp":1613008235000},"page":"e538-e546","source":"Crossref","is-referenced-by-count":15,"title":["Nortriptyline for pain in knee osteoarthritis: a double-blind randomised controlled trial in New Zealand general practice"],"prefix":"10.3399","volume":"71","author":[{"given":"Ben","family":"Hudson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A","family":"Williman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Alchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Mangin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn F Lenox","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Les","family":"Toop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"issue":"10","key":"2022062908501990000_71.708.e538.1","doi-asserted-by":"crossref","first-page":"e0185676","DOI":"10.1371\/journal.pone.0185676","article-title":"The quality-of-life burden of knee osteoarthritis in New Zealand adults: a model-based evaluation","volume":"12","author":"Abbott","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"2022062908501990000_71.708.e538.2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/acr.22412","article-title":"Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty","volume":"67","author":"Losina","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2022062908501990000_71.708.e538.3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-8-59"},{"key":"2022062908501990000_71.708.e538.4","unstructured":"Access Economics (2010) The economic cost of arthritis in New Zealand in 2010, https:\/\/www.arthritis.org.nz\/pdfs\/economic-cost-of-arthritis-in-newzealand-final-print.pdf (accessed 21 May 2021)."},{"key":"2022062908501990000_71.708.e538.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"2022062908501990000_71.708.e538.6","unstructured":"National Institute for Health and Care Excellence (2020) Osteoarthritis: care and management, Clinical guideline [CG177], http:\/\/nice.org.uk\/cg177 (accessed 21 May 2021)."},{"key":"2022062908501990000_71.708.e538.7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013273"},{"key":"2022062908501990000_71.708.e538.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206914"},{"key":"2022062908501990000_71.708.e538.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31744-0"},{"key":"2022062908501990000_71.708.e538.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60900-9"},{"key":"2022062908501990000_71.708.e538.11","doi-asserted-by":"crossref","unstructured":"da Costa BR N\u00fcesch E Kasteler R (2014) Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 9, CD003115.","DOI":"10.1002\/14651858.CD003115.pub4"},{"key":"2022062908501990000_71.708.e538.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2018.03.009"},{"key":"2022062908501990000_71.708.e538.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0899"},{"key":"2022062908501990000_71.708.e538.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.5283"},{"issue":"1377","key":"2022062908501990000_71.708.e538.15","first-page":"7","article-title":"Quantifying the demand for hip and knee replacement in Otago, New Zealand","volume":"126","author":"Gwynne-Jones","year":"2013","journal-title":"N Z Med J"},{"issue":"10077","key":"2022062908501990000_71.708.e538.16","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(17)30059-4","article-title":"The effect of patient age at intervention on risk of implant revision after total replacement of the hip or knee: a population-based cohort study","volume":"389","author":"Bayliss","year":"2017","journal-title":"Lancet"},{"key":"2022062908501990000_71.708.e538.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100759"},{"key":"2022062908501990000_71.708.e538.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204191"},{"issue":"7","key":"2022062908501990000_71.708.e538.19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/pme.12800","article-title":"Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials","volume":"16","author":"Wang","year":"2015","journal-title":"Pain Med"},{"issue":"5","key":"2022062908501990000_71.708.e538.20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1526-4637.2009.00637.x","article-title":"A single-blind placebo run-in study of venlafaxine XR for activity-limiting osteoarthritis pain","volume":"10","author":"Sullivan","year":"2009","journal-title":"Pain Med"},{"key":"2022062908501990000_71.708.e538.21","doi-asserted-by":"crossref","unstructured":"Saarto T Wiffen PJ (2007) Antidepressants for neuropathic pain. Cochrane Database Syst Rev 4, CD005454.","DOI":"10.1002\/14651858.CD005454.pub2"},{"key":"2022062908501990000_71.708.e538.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5222"},{"key":"2022062908501990000_71.708.e538.23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s13063-015-0961-1","article-title":"Nortriptyline in knee osteoarthritis (NortIKA Study): study protocol for a randomised controlled trial","volume":"16","author":"Hudson","year":"2015","journal-title":"Trials"},{"key":"2022062908501990000_71.708.e538.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"2022062908501990000_71.708.e538.25","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-10-200411160-00009"},{"key":"2022062908501990000_71.708.e538.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290816"},{"issue":"12","key":"2022062908501990000_71.708.e538.27","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"2022062908501990000_71.708.e538.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2004.02.001"},{"key":"2022062908501990000_71.708.e538.29","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4730020305"},{"issue":"4","key":"2022062908501990000_71.708.e538.30","first-page":"469","article-title":"Dimensionality and summary measures of the SF-36 v1.6: comparison of scale- and item-based approach across ECRHS II adults population","volume":"13","author":"Grassi","year":"2010","journal-title":"Value Health"},{"key":"2022062908501990000_71.708.e538.31","unstructured":"National Cancer Institute (2021) Common Terminology Criteria for Adverse Events (CTCAE): Version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50 (accessed 17 May 2021)."},{"key":"2022062908501990000_71.708.e538.32","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.061960"},{"issue":"11","key":"2022062908501990000_71.708.e538.33","first-page":"2635","article-title":"Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis","volume":"27","author":"Ehrich","year":"2000","journal-title":"J Rheumatol"},{"key":"2022062908501990000_71.708.e538.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2003.11.006"},{"issue":"7","key":"2022062908501990000_71.708.e538.35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v045.i07","article-title":"Amelia II: a program for missing data","volume":"45","author":"Honaker","year":"2011","journal-title":"Journal of Statistical Software"},{"key":"2022062908501990000_71.708.e538.36","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-11-85"},{"key":"2022062908501990000_71.708.e538.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1063-4584(05)80101-3"},{"key":"2022062908501990000_71.708.e538.38","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)45:5<453::AID-ART365>3.0.CO;2-W"},{"issue":"S5","key":"2022062908501990000_71.708.e538.39","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1002\/art.11401","article-title":"Measures of adult lower extremity function: The American Academy of Orthopedic Surgeons Lower Limb Questionnaire, The Activities of Daily Living Scale of the Knee Outcome Survey (ADLS), Foot Function Index (FFI), Functional Assessment System (FAS), Harris Hip Score (HHS), Index of Severity for Hip Osteoarthritis (ISH), Index of Severity for Knee Osteoarthritis (ISK), Knee Injury and Osteoarthritis Outcome Score (KOOS), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC\u2122)","volume":"49","author":"Rogers","year":"2003","journal-title":"Arthritis Care Res"},{"key":"2022062908501990000_71.708.e538.40","unstructured":"New Zealand Government (2021) New Zealand consumer medicine information Norpress: nortriptyline (as hydrochloride) 10mg & 25mg tablets, https:\/\/www.medsafe.govt.nz\/Consumers\/CMI\/n\/norpress.pdf (accessed 18 May 2021)."},{"key":"2022062908501990000_71.708.e538.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7240.987"},{"key":"2022062908501990000_71.708.e538.42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu244"},{"key":"2022062908501990000_71.708.e538.43","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"2022062908501990000_71.708.e538.44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.944"},{"key":"2022062908501990000_71.708.e538.45","doi-asserted-by":"publisher","DOI":"10.1186\/ar4441"},{"issue":"11","key":"2022062908501990000_71.708.e538.46","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2018.4222","article-title":"Efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial","volume":"178","author":"Urquhart","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2022062908501990000_71.708.e538.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2011.03.007"},{"key":"2022062908501990000_71.708.e538.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2013.06.023"}],"container-title":["British Journal of General Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGP.2020.0797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T15:54:28Z","timestamp":1656518068000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgp.org\/lookup\/doi\/10.3399\/BJGP.2020.0797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":48,"journal-issue":{"issue":"708","published-online":{"date-parts":[[2021,6,24]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.3399\/BJGP.2020.0797"],"URL":"https:\/\/doi.org\/10.3399\/bjgp.2020.0797","relation":{},"ISSN":["0960-1643","1478-5242"],"issn-type":[{"value":"0960-1643","type":"print"},{"value":"1478-5242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]}}}